Skip to content
Screener

Fulgent Genetics, Inc. FLGT Therapeutic Development — Total Assets

Other segment segments

Laboratory Services
$1.05B-6.2%

Similar metrics at other companies

CPH
CPHCDevelopment — Total Assets
$35.68M-5.5%
FRP Holdings logo
FRPHDevelopment — Total Assets
$227.23M+93.2%
Pure Cycle logo
PCYOLand Development — Total Assets
$8.33M-27.6%
Newell Brands logo
NWLLearning and Development — Total Assets
$3.85B-0.4%
SBA Communications logo
SBACSite Development Construction — Total Assets
$81.13M-13.2%
Restoration Hardware logo
RHReal Estate Development — Total Assets
$151.6M-2.9%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%—

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0×0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemMarch 31, 2026December 31, 2025
Laboratory services$1,047,231$1,096,379
Therapeutic development109,138117,146
Total$1,156,369$1,213,525

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s therapeutic development — total assets?
Fulgent Genetics, Inc. (FLGT) reported therapeutic development — total assets of $109.14M in Q1 2026.
How has Fulgent Genetics, Inc.'s therapeutic development — total assets changed year-over-year?
Fulgent Genetics, Inc.'s therapeutic development — total assets increased by 22.8% year-over-year, from $88.9M to $109.14M.
What does therapeutic development — total assets mean?
Represents the total economic resources controlled by the therapeutic development segment used to support drug discovery and clinical research activities. This metric tracks the capital intensity required to maintain the segment's research infrastructure and intellectual property portfolio.

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude